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Abstract
Papain-like cysteine proteases are important for the survival of the flagellated
protozoa Trypanosoma cruzi, the causative agent of Chagas’ Disease. The lysosomal
cysteine protease designated as cruzipain or cruzain, is the archetype of a multi-
gene family of related isoforms. We investigated the substrate specificity of the
cruzipain 2 isoform using internally quenched fluorogenic substrates. We found
that cruzipain 2 and cruzain differ substantially regarding the specificity in the S2,
S01 and S
0
2 pockets. Our study indicates that cruzipain 2 has a more restricted
specificity than cruzain, suggesting that these isoforms might act on distinct
natural substrates.
Introduction
Cysteine proteases are regarded as essential for the survival of
several parasitic protozoa (reviewed in Sajid & McKerrow,
2002). In Trypanosoma cruzi, the etiological agent of Chagas’
Disease, the major cysteine protease, cruzipain, has been the
subject of extensive biochemical and structural studies in the
past decade (reviewed in Cazzulo et al., 1997). Studies using
synthetic irreversible cysteine protease inhibitors in vitro and
in vivo validated cruzipain as a potential chemotherapeutical
target (Meirelles et al., 1992; Harth et al., 1993; Engel et al.,
1998). Cruzipain is a papain-like proteinase, which shares
biochemical characteristics with both cathepsin L and
cathepsin B (Cazzulo et al., 1990a; Murta et al., 1990; Lima
et al., 1992). As other papain-like enzymes, it is synthesized
as a proenzyme that undergoes maturation by proteolytic
excision of the N-terminal prodomain. However, unlike its
mammalian counterparts, cruzipain has an unusual highly
glycosylated 130 amino acids carboxy-terminal extension,
with unknown function, which is not required for proteoly-
tic activity (Aslund et al., 1990; Eakin et al., 1992).
Although cruzipain was operationally defined as the
major cysteine proteinase detected in T. cruzi epimastigotes
(the noninfective stage found in the insect vector), this
protease is a member of a large multigene family composed
of polymorphic genes (Campetella et al., 1992; Lima et al.,
1994), whose expression are stage regulated in the parasite
(Tomas & Kelly, 1996). Studies using reverse transcriptase
PCR (RT-PCR) showed that in epimastigotes the majority
of cruzipain RNA encodes highly similar isoforms
(4 95% amino acid identity), while in trypomastigotes and
amastigotes, the mammalian stages of the parasite, the
expression of more divergent cruzipain genes can be
detected (Lima et al., 1994). The majority of the biochemical
studies on cruzipain were performed using the natural
enzyme purified from epimastigotes (Cazzulo et al., 1990b;
Parodi et al., 1995; Cazzulo et al., 1996; Serveau
et al., 1996; Nery et al., 1997; Meldal et al., 1998; Serveau
et al., 1999). For simplicity, we refer to the major isoform
isolated from epimastigotes as cruzipain 1 (n-cruzipain 1).
A representative member of the cruzipain-1 complex was
expressed in Escherichia coli truncated at the C-terminus and
the recombinant enzyme was named cruzain (r-cruzain)
(Eakin et al., 1992). The resolution of r-cruzain’s X-ray
structure revealed details about structure-function, leading
to the design of specific inhibitors with potent trypanocidal
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activity (McGrath et al., 1995; Gillmor et al., 1997). Struc-
tural studies showed that the active site region of r-cruzain is
very similar to that of other papain-like members, extending
over seven substrate-binding sites, four of which (S4–S1) are
located on the acyl side of the cleaved bond and three
(S01  S03) on the amino side (McGrath et al., 1995; Gillmor
et al., 1997). Previous studies defined the contribution of the
substrate residues interacting with each of the subsites to the
specificity of n-cruzipain 1 purified from epimastigotes
(Nery et al., 1997). Subsequently, a systematic study regard-
ing the specificity of r-cruzain was reported (Judice et al.,
2001).
Although the kinetic properties of n-cruzipain 1 were
studied in detail, little is known about the functional
properties of the divergent isoforms. The characterization
of one of these isoforms, cruzipain 2 (r-cruzipain 2),
expressed truncated at the carboxy terminus in Saccharo-
myces cerevisiae, revealed an enzyme presenting substrate
preference and susceptibility to inactivation by inhibitors
distinct from those of r-cruzain (Lima et al., 2001). Cruzi-
pain 2 is preferentially expressed by trypomastigotes and
amastigotes, the mammalian stages of the parasite. Given
the potential functional diversity between cruzipain iso-
forms, it becomes important for drug-design strategies the
characterization of the biochemical and kinetic properties
of these enzymes. In this work, we refined the analysis of
the substrate specificity of r-cruzipain 2 using internally
quenched fluorescent peptides with ortho-amino benzoic
acid (Abz) and N-[2,4-dinitrophenyl]-ethylenediamine
(EDDnp) fluorescence donor and receptor groups, respec-
tively. We showed that r-cruzipain 2 diverges from r-cruzain





subsites, and discussed the implications of these findings.
Materials and methods
Recombinant enzyme and substrates
Recombinant cruzipain 2 was expressed and purified as
described previously (Lima et al., 2001). Cruzain was a gift
from J. McKerrow (UCSF, San Francisco). The intramolecu-
larly quenched fluorogenic substrates were synthesized by
solid phase synthesis as described previously (Meldal et al.,
1998). Briefly: Na-fluoren-a-ylmethoxycarbonyl-Glu(aCO)-
N-EDDnp was attached to benzhydrylamino resin through
as p-{(R,S)- a-[1-(9H-fluoren-9-yl)methoxyformamido]-2,
4-dimethoxybenzylphenoxyacetic acid} linker and the pep-
tides were synthesized by fluoren-a-ylmethoxycarbonyl
methodology using a multiple automated peptide synthesi-
zer PSSM-8 (Shimadzu). Each substrate was diluted at
1mgmL1 in dimethyl sulfoxide (DMSO) and the molar
concentration was determined as follows: substrates were
diluted 50 times in reaction buffer and the optical density at
365 nm was measured in a spectrophotometer, the concen-
tration was determined using e= 17 300M1 cm1.
Kinetics
The hydrolysis of the substrates were monitored in contin-
uous assays by measuring the fluorescence at 320 nm excita-
tion and 420 nm emission in a F4500 (Hitachi) fluorimeter,
in 50mM Na2HPO4, 100mM NaCl, 5mM EDTA, pH 6.5,
5% DMSO, 5mM dithiothreitol, at 30 1C, using a Hitachi F-
4500. To ensure stability, the enzymes were kept on ice until
assayed. The initial velocities were calculated by linear
regression of the substrate hydrolysis curves. The enzyme
concentration was determined by active site titration using
recombinant human cystatin C (a gift from M. Abraham-
son). The titration was performed upon incubation of the
enzymes with various inhibitor concentrations at room
temperature for 1 h. The remaining activity was measured
upon addition of e-NH2(Cap)-L-(SBzl)C-AMC (Nery et al.,
1997) at a final concentration of 10 mM. The kinetic para-
meters Km and kcat were determined using the Michaelis and
Menten equation on Graffit 3.0 for Windows to fit V0 [S]
curves. The kinetics were performed at least three indepen-
dent times with each substrate.
Results and discussion
Influence of the P3, P2 and P1 residues in the
substrate specificity of cruzipain 2
We used seven residues intramolecularly quenched fluoro-
genic Abz-peptidyl-EDDnp substrates containing systematic
substitutions in either side of the scissile bond to evaluate
the contribution of these positions in the kinetic parameters
of recombinant cruzipain 2 (r-cruzipain 2) (Table 1). In
contrast with di- or tri-peptidyl-MCA substrates, the use of
longer substrates, which span the entire active site of papain-
like proteases, allows a more accurate determination of the
specificity restrains of this isoform. This series of substrates
was previously used in the investigation of the substrate
specificity of r-cruzain (Judice et al., 2001), allowing the
comparison of the kinetic properties of these isoforms. We
found that the activity (kcat/Km) of r-cruzipain 2 was
consistently lower as compared with r-cruzain, mainly due
to Km values five to 20 times higher than those of r-cruzain
(Judice et al., 2001). The scan of substrates with substitu-
tions in the P1 position revealed that r-cruzipain 2 presents a
marked preference for positively charged residues in this
position, showing a slight (twofold) preference for Arg over
Lys. Consistent with previous results using peptidyl-MCA
substrates, r-cruzipain 2 also presented distinctively higher
activity towards the substrate containing (SBz)Cys in P1
(Lima et al., 2001), discriminating it from substrates con-
taining Phe or Gly at this position. Although the preference
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for positive residues in P1 is shared with r-cruzain, the latter
does not discriminate (SBz)Cys from Phe or Gly in P1
(Judice et al., 2001).
The evaluation of the S2 subsite specificity showed that,
differently from n-cruzipain 1 or r-cruzain, r-cruzipain 2
selects for Leu in the P2 position, displaying a marked
preference (10-fold) for Leu over Phe in P2. The previous
characterization of r-cruzain with the same substrate series
showed that Phe and Leu are accepted in P2, with a slight
preference (twofold) for Leu over Phe (Lima et al., 2001).
This result suggests that the S2 pocket of r-cruzipain 2 might
be more restricted than that of r-cruzain, as the latter accepts
equally well bulky and small hydrophobic or basic residues
in P2 (Nery et al., 1997; Judice et al., 2001). This is in
agreement with previous results showing that the hydrolysis
of Z-Phe-Arg-MCA by r-cruzipain 2 was rather inefficient
(Lima et al., 2001). Structural studies of r-cruzain in
complex with irreversible inhibitors showed that residues
Leu67, Ala133 and Leu157 lined with the S2 pocket readily
accommodate the Phe residue at P2, which interacts with the
enzyme’s backbone via the carbonyl of Gly66 (Brinen et al.,
2000). We might speculate that the Ser133 substitution
found in cruzipain 2, combined with the proximal change
of Met68 to Ser68 in cruzipain 2, may ultimately influence
the enzyme’s S2 specificity. Studies of molecular modeling
suggest that this subsite is narrower in cruzipain 2 as
compared with cruzain (L. Dardenne and P. Bisch, unpub-
lished data), possibly justifying the poor accommodation of
Phe in the S2 pocket of r-cruzipain 2. Interestingly, the
marked preference for Leu over Phe in P2 is a feature
observed with mammalian cathepsins S and K, but not with
cathepsins L, F or B (Wang et al., 1998). Although cathepsins
L, S and F can be concomitantly expressed in the same cell
type, studies with knock-out mice revealed that these
enzymes do not play redundant roles (Nagler & Me´nard,
2003).
R-cruzipain 2 was also able to hydrolyze a substrate
containing a positively charged residue in P2 (Arg), a feature
of cathepsin B. This functional property was previously
demonstrated in studies with either n-cruzipain 1 or r-
cruzain (Lima et al., 1992; Nery et al., 1997; Judice et al.,
2001), being attributed to the presence of a Glu residue at
the bottom of the S2 pocket, which interacts with the
positive charge, stabilizing basic residues in the pocket
(Gillmor et al., 1997). Indeed, a Glu residue is also present
at position 208 (cruzain numbering) of the cruzipain 2
sequence (Lima et al., 1994). When Pro was present in P2,
the efficiency of hydrolysis of the substrate was 100-fold
lower than that observed when Leu was in P2, both due to
low affinity and low Kcat values. This is in contrast with the
Table 1. Kinetic parameters for the hydrolysis of fluorogenic substrates by cruzipain 2
Substrate variations Substrates Km (mM) kcat (s
1) kcat/Km (mM
1 s1)
Reference substrate Abz-KLR # FSKQ-EDDnp 2.2 6.9 3090
(SBz)Cys 5.8 10.8 1862
Abz-KLX # FSKQ-EDDnp (P1) Phe 2.8 2.5 892
Lys 7.9 14.2 1797
Gly 11.4 5.6 491
Arg 7.3 4.3 589
Abz-KXR # FSKQ-EDDnp (P2) Phe 5.1 1.9 372
Ala 6.0 1.3 227
Pro 11.7 0.5 43
Arg 3.2 7.7 2406
Abz-XLR # FSKQ-EDDnp (P3) Leu 3.6 6.7 1861
His 2.1 5.6 2667
Ala 4.4 4.5 1023
Ala 10.5 7.7 733
Abz-KLR # XSKQ-EDDnp (P01) Leu 3.8 9.1 2395
Arg 13.2 1.9 144
Pro No hydrolysis was detected
Arg 11.4 9.8 860
Abz-KLR # FXKQ-EDDnp (P02) Phe 4.6 9.7 2109
Ala 5.1 8.2 1607
Pro 7.9 2.8 354
Ala 4.0 15.2 3800
Abz-KLR # FSXQ-EDDnp (P03) Arg 4.6 12.5 2717
Phe No hydrolysis was detected
Pro 7.8 13.9 1782
The errors were kept below 15% in all points. The conditions of hydrolysis: 50 mM Na2HPO4, 100 mM NaCl, 5 mM EDTA, pH 6.5, 5% DMSO, 5 mM
dithiothreitol, at 30 1C.
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results obtained with r-cruzain, which tolerates Pro in P2
showing only a 10-fold reduction in the Kcat/Km, as com-
pared with the substrate containing Leu in P2 (Judice et al.,
2001). As the S2 subsite is considered the only well-defined
and true specificity pocket of papain-like proteases (Turk
et al., 1998), differences in S2 specificity suggest that these
isoforms might be tailored to process distinct natural
substrates or the same substrate at alternative cleavage sites.
When the residues in P3 were varied, we did not observe
any significant change in enzyme activity, which is in
agreement with the notion that the residues in this position
make only superficial contact with papain-like enzymes and
are not likely to have an influence in the enzyme specificity.
Influence of the P10 , P20 and P30 residues in the
substrate specificity of cruzipain 2
R-cruzipain 2 also displayed a more restricted specificity
than n-cruzipain 1 or r-cruzain when we evaluated substitu-
tions at the P01 position. While n-cruzipain 1 and r-cruzain
accept equally hydrophobic residues (Leu, Phe and Ala) or
basic residues (Arg) in P01, r-cruzipain 2 displayed a 20-fold
preference for Leu or Phe over Arg. In addition, r-cruzipain
2 also showed a fivefold reduction in the efficiency of
hydrolysis when Ala was in this position, indicating that the
enzyme markedly selects for hydrophobic residues in P01. A
study of the structural determinants of the S01 specificity of
r-cruzain in complex with inhibitors revealed that extensive
hydrogen bonding and electrostatic interactions in this area
rather than aromatic interactions are important for specifi-
city (Brinen et al., 2000). Noteworthy, interactions of the
residue in P01 of the inhibitor with Asp158 were observed,
and the substitution of this residue by Ser158 in cruzipain 2
might constrain the accommodation of Arg in the S01 of
r-cruzipain 2.
R-cruzipain 2 accommodated Ser, Phe or Ala equally in
P02 but the substrate containing Pro was hydrolyzed poorly,
mostly due to lower Kcat values. This is in contrast with
previous characterization of r-cruzain, which hydrolyzed
with similar efficiency the above-mentioned substrates,
independently of the nature of the residue present in P02
(Judice et al., 2001). The efficient cleavage of a substrate with
Pro at P02 by r-cruzain may have biological implications
because of the nature of the cleavage site (VVG # APA)
involved in the autocatalytic processing of zymogens. Of
note, this cleavage site is shared by both isoforms. We may
anticipate that cruzipain 2 zymogens may not undergo
efficient self-maturation, thus depending on cruzipain 1 for
trans-activation. If true, the in vivo effects of inhibitors
designed against cruzipain 1 may be enhanced due to
impaired procruzipain 2 trans-activation by cruzipain 1.
As expected, substitutions in the P03 position did not
significantly affect substrate hydrolysis by r-cruzipain 2, and
we found similar results when investigated the influence of
P03 in the specificity of r-cruzain (not shown). Surprisingly,
and in contrast to the observed with r-cruzain, we were
unable to detect hydrolysis of the substrate containing Phe at
P03 by r-cruzipain 2. This observation suggests that the
residue in this position possibly makes important contacts
with the enzyme surface, a property that may be explored in
the design of inhibitors partially selective to r-cruzain over r-
cruzipain 2.
We have reported that r-cruzipain 2 is mainly expressed
by amastigotes and trypomastigotes (Lima et al., 2001). It is
of note that both n-cruzipain 1 and n-cruzipain 2 may
participate cooperatively in relevant biological processes
such as host cell signaling and invasion by T. cruzi (Scharf-
stein et al., 2000; Aparicio et al., 2004). Additional studies
are required to clarify if T. cruzi is able to exploit the
repertoire of functionally diverse cruzipain isoforms to
invade a broad range of host cells (Scharfstein, 2003). The
combined differences in specificity observed in r-cruzipain
2, as compared with r-cruzain, could be exploited in the
design of partially selective inhibitors, aiming at the study of
independent contribution of theses activities to the physiol-
ogy of Trypanosoma cruzi.
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